Keymeulen, Bart http://orcid.org/0000-0002-8671-4527
De Groot, Kaat http://orcid.org/0000-0003-1852-5465
Jacobs-Tulleneers-Thevissen, Daniel http://orcid.org/0000-0001-5758-9547
Thompson, David M.
Bellin, Melena D.
Kroon, Evert J. http://orcid.org/0000-0002-4069-3644
Daniels, Mark
Wang, Richard http://orcid.org/0000-0003-0079-9214
Jaiman, Manasi
Kieffer, Timothy J.
Foyt, Howard L. http://orcid.org/0000-0002-5209-1261
Pipeleers, Daniel http://orcid.org/0000-0002-6440-2485
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (681070, 681070, 681070, 681070)
JDRF (2-SRA-2019-708, 2-SRA-201-708, 2-SRA-2019-708)
Fonds Wetenschappelijk Onderzoek (11B5621N)
California Institute for Regenerative Medicine (CLIN2-09672, CLIN2-09672, CLIN2-09672, CLIN2-09672, CLIN2-09672, CLIN2-09672, CLIN2-09672, CLIN2-09672)
Article History
Received: 5 July 2022
Accepted: 5 November 2023
First Online: 27 November 2023
Competing interests
: E.J.K, M.D., R.W., M.S.J., T.J.K. and H.L.F were employees of ViaCyte, Inc., a privately held company that produces PEC-Direct. M.D.B. declares consulting/DSMB memberships for Insulet, Vertex and Emerging Therapy Solutions. D.P. declares non-financial competing interests as a member of the ViaCyte Clinical Advisory Board. B.K., K.D.G., D.J.-T.-T. and D.M.T. declare no competing interests.